SecBot SecBot
PRESS-RELEASE ·Filed Apr 9, 2026

CCCC

C4 Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight ▲ Bullish

The partnership with Roche validates C4T's TORPEDO® platform and provides non-dilutive funding. Traders should monitor milestone achievements and potential stock movement on future announcements, especially as DACs represent a novel modality with high upside in oncology.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$2.83
T+0 close · Apr 9, 2026 · via day close
Latest settled
+46.29%
T+60 · $4.14
Vs SPY
+35.51%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 9 $2.83entry
  2. T+1 · 7mo ago −10.42%α −10.36% · $2.54
  3. T+5 · 7mo ago +2.47%α −0.71% · $2.90
  4. T+20 · 6mo ago +3.53%α −4.03% · $2.93
  5. T+60 · 4mo ago +46.29%α +35.51% · $4.14
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

C4 Therapeutics announced a collaboration with Roche to develop degrader-antibody conjugates (DACs) for two oncology targets, with an option for a third. C4T receives a $20 million upfront payment and is eligible for over $1 billion in potential milestone payments and future royalties.

Key Financial Metrics

Deal Value
$20.0M

Key Facts

  • C4 Therapeutics entered a collaboration with Roche to develop degrader-antibody conjugates (DACs) for oncology targets.
  • C4T will receive $20 million upfront and is eligible for over $1 billion in discovery, development, and commercial milestone payments.
  • Roche will handle conjugation, preclinical/clinical development, and commercialization; C4T will design degrader payloads using its TORPEDO® platform.
  • The deal includes tiered royalties on future sales, subject to reductions under certain circumstances.

Financial Impact

$20 million upfront and over $1 billion in potential milestones

cashrevenuefuture royalties

Risk Factors

  • Milestones are contingent on successful development and regulatory progress, which are uncertain.
  • Royalty terms may be reduced under certain circumstances as outlined in the agreement.
  • Failure of DAC candidates in preclinical or clinical stages could negatively impact valuation.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3270765

Track record

19 reports on CCCC

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +46.29% at T+60 after the Apr 9, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.71 Now $2.65 −2.03% settles Nov 23
  2. Nov 12, 20264d ago 144 Neutral 2/10 Entry $2.76 Now $2.65 −3.99% settles Nov 20
  3. Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $3.10 to $2.76 Now $2.65 −14.52% ▼ −10.97% −13.56% vs SPY
  4. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $2.95 to $2.77 Now $2.65 −10.17% ▼ −6.10% −9.39% vs SPY
  6. Sep 25, 20267w ago 8-K Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
  7. Sep 25, 20267w ago Press Release Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
  8. Aug 14, 202613w ago 144 Neutral 3/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
  9. Aug 14, 202613w ago Institutional Cluster Bullish 6/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
  10. Aug 11, 202613w ago 8-K Neutral 5/10 Entry $3.87 to $4.18 Now $2.65 −31.52% ▲ +8.01% +8.41% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 9, 2026